Australian biotech market today 13.03.09
Friday, 13 March, 2009
Biotech and pharma stocks were up 1.5 per cent on trading at 2pm compared to a rise in the All Ordinaries of three per cent, on a good day for the Australian sharemarket overall.
Alchemia (ASX:ACL) is up 5c on news that its manufacturing partner Dr Reddy’s Laboratories had filed a new drug application with the US FDA for a generic version of fondaparinux, an anti-coagulant used for treating blood clots.
pSivida (ASX:PVA) was up eight per cent to $1 following its report of good interim results in a Phase II trial of an intra-vitreal insert for diabetic macular oedema.
CSL (ASX:CSL) is up 40c but is still down on its year high of $38.50, while Sonic Healthcare recovered 40c on yesterday’s year low of $9.96.
Acrux (ASX:ACR) and Cellestis (ASX:CST) were up slightly on very small volumes.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...